Literature DB >> 12708620

Partial fatty acid oxidation (pFOX) inhibition: a new therapy for chronic stable angina.

C Richard Conti.   

Abstract

During myocardial ischemia, fatty acids are the principal source of energy, increasing myocardial oxygen consumption and making a decrease in coronary blood flow less well tolerated. Increasing glucose oxidation during myocardial ischemia may improve cardiac efficiency. The pFOX inhibitors have the potential to accomplish this. In 2003, I think we can look forward to learning more about this class of compounds called pFOX inhibitors. Perhaps they will provide us alternative therapies in our patients who have persistent chronic stable angina pectoris despite aggressive medical therapy and/or revascularization. It seems to methat this is an increasing problem, and it is particularly common in older patients who want to remain active, but whose chronic stable angina interferes with that lifestyle.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12708620      PMCID: PMC6654658          DOI: 10.1002/clc.4960260402

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  2 in total

1.  Ranolazine attenuated heightened plasma norepinephrine and B-Type natriuretic peptide-45 in improving cardiac function in rats with chronic ischemic heart failure.

Authors:  Guangqiu Feng; Yu Yang; Juan Chen; Zhiyong Wu; Yin Zheng; Wei Li; Wenxin Dai; Pin Guan; Chunrong Zhong
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

2.  Ranolazine: ion-channel-blocking actions and in vivo electrophysiological effects.

Authors:  Gernot Schram; Liming Zhang; Katayoun Derakhchan; Joachim R Ehrlich; Luiz Belardinelli; Stanley Nattel
Journal:  Br J Pharmacol       Date:  2004-07-26       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.